Informed Prostate Cancer Patient Support

lncRNA-mRNA network analysis reveals novel biomarkers in prostate adenocarcinoma | bioRxiv Prostate adenocarcinoma (PRAD) is the second most frequent cancer among men worldwide. lncRNAs have been suggested as novel promising biomarkers for cancer diagnosis and prognosis and therapeutic targets. Despite the previous investigations, still, comprehensive studies are required to discover the regulatory roles of lncRNAs in PRAD. We introduced a PRAD lncRNA-mRNA network (PLMNET) to identify novel PRAD biomarkers and therapeutic targets among lncRNAs. The PLMNET is constructed based on RNAs that are differentially expressed and had strongly correlate with each other. PANTR1, HOXB-AS3, EMX2OS, GATA3-AS1, LINC01116, LINC02385 are PLMNET hubs that are considered key regulatory lncRNAs of PRAD. We also mapped PLMNET lncRNAs to their associated GO-terms and hallmarks. Literature review confirms our suggested biomarkers and their associated hallmarks. The high degree nodes of PLMNET, GA...

Methionine Restriction and Cancer Biology - PMC ncbi.nlm.nih.gov Methionine Restriction and Cancer Biology Desiree Wanders, Katherine Hobson, and Xiangming Ji* 56–71 minutes Journal List Nutrients PMC7146589 Abstract The essential amino acid, methionine, is important for cancer cell growth and metabolism. A growing body of evidence indicates that methionine restriction inhibits cancer cell growth and may enhance the efficacy of chemotherapeutic agents. This review summarizes the efficacy and mechanism of action of methionine restriction on hallmarks of cancer in vitro and in vivo. The review highlights the role of glutathione formation, polyamine synthesis, and methyl group do...